DBV Technologies | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Acadia Pharmaceuticals USD 237.8M 72.86M 2024-12
Alnylam Pharmaceuticals USD 490.35M 75.33M 2024-12
Amarin USD 16.28M 26.49M 2024-09
BioMarin Pharmaceutical USD 611.17M 53.89M 2024-12
DBV Technologies -30442000 30.56M 2024-09
Halozyme Therapeutics USD 255.95M 15.3M 2024-12
Incyte USD 1.1B 38.34M 2024-12
Insmed USD 78.29M 6.04M 2024-12
Ionis Pharmaceuticals USD 222.75M 90M 2024-12
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
PTC Therapeutics USD 196.89M 10.95M 2024-12
Sarepta Therapeutics USD 526.11M 150.63M 2024-12
Ultragenyx Pharmaceutical USD 147.98M 29.51M 2024-12
United Therapeutics USD 660M 5.8M 2024-12



DBV Technologies Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.